Table 2.
Up- and Down-regulated miRs in advanced coronary atherosclerotic plaques (CAP versus non-atherosclerotic a. mammaria samples (IMA).
| miRNA | IMA | CAP | Fold change | P-values | ||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| let-7f | −0.217 | 0.834 | −4.954 | 1.384 | −4.7 | 0.001 |
| miR-1 | −0.559 | 3.772 | −5.654 | 1.104 | −4.7 | 0.001 |
| miR-9 | −3.307 | 1.793 | −4.146 | 1.298 | −2.4 | 0.05 |
| miR-19b | −0.079 | 1.375 | 3.998 | 1.321 | 2.7 | 0.05 |
| miR-21 | −0.106 | 2.026 | 5.685 | 1.289 | 4.5 | 0.001 |
| miR-22 | −0.183 | 0.997 | −4.980 | 2.323 | −4.5 | 0.05 |
| miR-29b | −1.098 | 1.287 | 4.011 | 1.165 | 2.8 | 0.05 |
| miR-92a | −1.061 | 1.505 | 3.768 | 1.322 | 2.6 | 0.05 |
| miR-99a | −1.061 | 1.334 | 4.979 | 1.278 | 3.8 | 0.001 |
| miR-143 | −0.188 | 1.777 | −3.090 | 1.384 | −2.7 | 0.05 |
| miR-223 | −0.172 | 1.397 | 3.694 | 1.537 | 3.5 | 0.05 |
miRs were detected with the SABiosciences Human miFinder RT² microRNA PCR Array in non-atherosclerotic a. mammaria samples (IMA, n = 4) or advanced coronary atherosclerotic plaques (CAP, n = 4). Relative mRNA quantification was performed and the fold change in the target miR, normalized to the internal control (SNORD 44) and relative to the expression in healthy controls, was calculated and presented (cut off >2). Significance was assumed at p < 0.05 (corrected p-values).